Snoretox Ltd.
Snoretox Ltd. is an innovative biotech company focused on developing a drug to treat Brachycephalic Obstructive Airways Syndrome (BOAS) and various human muscle weakness conditions. Based in Melbourne, Australia, the company has patented a novel therapeutic that utilizes modified tetanus toxin to enhance muscle tone, similar to how Botox works with botulinum toxin. Their mission is to improve the quality of life for individuals suffering from muscle-related disorders through groundbreaking biotherapeutics.
What We Do
Snoretox™
A therapeutic for treating sleep apnoea and snoring, utilizing modified tetanus toxin for muscle toning.
Tonetox™
A therapeutic for various muscle weakness conditions, leveraging modified tetanus toxin technology.
Application Area
Psychological and Cognitive Health and Performance
Key People
Dr. Tony Sasse
Founder
Professor Peter Smooker
Biotechnologist
Mr. John Mitchell
Business/Governance Expert
Dr. Dennis Feeney
Founder of Venture Technology Group
Dr. Natasha Monin
Medical Executive
News & Updates
Snoretox has been awarded a $1 million grant from the Medical Research Future Fund to support its research and development efforts.
Snoretox was highlighted in a funding announcement by Premier Dan Andrews, receiving recognition for its innovative technology.
Snoretox's drug has received a Barrier to Innovation Waiver from the FDA's veterinarian department, enhancing its credibility in the market.
Snoretox's research was published in Molecular Immunology, highlighting the scientific basis of its therapeutic approach.
Secured a $1 million grant to support the development of its muscle toning therapeutics.
Received a waiver from the FDA, recognizing the innovative nature of its therapeutic approach.